Artera Launches Real-World Registry to Track AI’s Impact in Cancer Care

What You Should Know: 

– Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announced the launch of its DIRECT-AI registry study. This new study will assess how the ArteraAI Prostate Test influences treatment decision-making between clinicians and patients with localized prostate cancer.

– The study will also monitor participants to evaluate their long-term cancer outcomes, reinforcing Artera’s commitment to advancing personalized cancer treatment and identifying future opportunities for test optimization.

Prostate Cancer Care Test

The DIRECT-AI study centers on the award-winning ArteraAI Prostate Test, which holds a unique position in the field. It is the only test included in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for localized prostate cancer that can both predict therapy benefit and prognosticate long-term outcomes.

The study is structured into two distinct phases to capture both immediate and long-term insights:

• Phase One: This initial phase will capture real-world data on how the ArteraAI Prostate Test informs clinical decision-making. Feedback will be collected directly from participating clinicians and their patients.
• Phase Two: The second phase will involve long-term monitoring of health outcomes at key intervals of 2 and 5 years. The study will look at critical endpoints such as distant metastasis, survival rates, and treatment effectiveness. This research will help Artera understand the real-world impact of its test and identify areas for future improvement.

How Patients and Clinics Can Participate

The study is designed to be seamless and non-interventional, meaning it does not require additional procedures or tests for participants.

• Patient Eligibility: Any patient receiving the commercial ArteraAI Prostate Test and whose ordering physician is associated with an enrolling clinic is eligible. Patients must have localized prostate cancer and must not have started or received treatment for their condition.
• Clinic Participation: For clinics participating in the DIRECT-AI Registry, physicians can easily enroll all patients for whom they order an ArteraAI Prostate Test into the study.

“Harnessing the power of AI, the ArteraAI Prostate Test marks a significant advancement in the personalized treatment of localized prostate cancer,” said Dr. Tim Showalter, Chief Medical Officer at Artera. “Through the DIRECT-AI registry, we are rigorously evaluating how this technology can enhance clinical decision-making and improve patient outcomes, providing clinicians and patients with the most accurate, tailored insights available.”